Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eptinezumab for Migraine and Vasomotor Symptoms in Perimenopause and Early Postmenopause
NCT07916571Phase 4Not yet recruiting
- Sponsor
- Alberta Neurologic Centre
- Start
- Feb 2027
- Primary completion
- Feb 2028
01
Overview
Phase 4, randomised, double-blind trial in migraine and vasomotor symptoms comparing Placebo -> Eptinezumab with Eptinezumab -> Eptinezumab (2 arms). Primary endpoint: Monthly Migraine Days at 12 weeks. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
eptinezumab
03
Conditions
migrainevasomotor symptoms
Beyond the preview
Go deeper on NCT07916571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07916571.